株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

経肺ドラッグデリバリー市場の予測 ~2021年:製剤タイプ (溶剤・懸濁液・ドライパウダー)・デバイスタイプ (MDI・DPI・ネブライザー)・キャニスター・エンドユーザー・用途別

Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021

発行 MarketsandMarkets 商品コード 447291
出版日 ページ情報 英文 153 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.20円で換算しております。
Back to Top
経肺ドラッグデリバリー市場の予測 ~2021年:製剤タイプ (溶剤・懸濁液・ドライパウダー)・デバイスタイプ (MDI・DPI・ネブライザー)・キャニスター・エンドユーザー・用途別 Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021
出版日: 2017年02月20日 ページ情報: 英文 153 Pages
概要

世界の経肺ドラッグデリバリーの市場は予測期間中、6.5%のCAGR (年間複合成長率) で推移し、2016年の361億米ドルから、2021年には523億7000万米ドルの規模に成長すると予測されています。経肺ルートによる投薬が好まれる傾向やスマート/デジタル吸入器の開発への焦点拡大、呼吸器系疾患の罹患率の上昇などの要因が同市場の成長を推進しています。

当レポートでは、経肺ドラッグデリバリーの市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、製剤区分・デバイスタイプ・キャニスタータイプ・用途・エンドユーザー・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

FIGURE 11 PULMONARY DRUG DELIVERY MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 経肺ドラッグデリバリー:市場概要
  • 地域市場の実績:用途別
  • 市場の実績・予測:デバイスタイプ別
  • ネブライザー市場の推移と予測:タイプ別
  • 地域概要

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 市場分析:製剤区分別

  • イントロダクション
  • 製剤タイプ
    • 懸濁エアロゾル
    • 溶液エアロゾル
    • 乾燥粉末製剤
  • デバイスタイプ
    • 定量噴霧式吸入器 (MDI)
    • ドライパウダー吸入器 (DPI)
    • ネブライザー
      • ジェットネブライザー
      • 超音波ネブライザー
      • ソフトミストネブライザー

第7章 市場分析:キャニスタータイプ別

  • イントロダクション
  • プレーンキャニスター
  • コーティングキャニスター

第8章 市場分析:用途別

  • イントロダクション
  • 慢性閉塞性肺疾患
  • 喘息
  • 嚢胞性線維症
  • その他

第9章 市場分析:エンドユーザー別

  • イントロダクション
  • 病院・診療所
  • 在宅医療

第10章 市場分析:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他
  • アジア
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第11章 競合環境

  • 概要
  • 市場ランキング
  • 競合状況・動向
    • 提携
    • 製品の投入・法規制上の承認
    • 買収
    • 拡張

第12章 企業プロファイル

  • イントロダクション
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 3M
  • GLAXOSMITHKLINE PLC
  • ASTRAZENECA PLC
  • BOEHRINGER INGELHEIM
  • MERCK & CO., INC.
  • NOVARTIS AG
  • オムロン
  • SUNOVION PHARMACEUTICALS INC.
  • CIPLA INC.
    • 概要
    • 製品・サービス
    • 財務動向
    • 戦略
    • 発展状況、など

第13章 付録

図表

目次
Product Code: MD 5021

The global pulmonary drug delivery market is projected to reach USD 52.37 billion by 2021 from USD 36.10 billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market.

The pulmonary drug delivery market is segmented based on formulations, canister type, applications, end users, and regions.

Based on canister type, the market is segmented into plain canister and coated canister. The coated canister segment is expected to witness the highest growth during the forecast period due to various advantages such as robust profile for filling, avoiding crimping, and withstanding the pressure associated with the type of propellant (HFAs or CFCs), minimizing formulation and canister interactions and avoids deposition of HFA on the canister surface.

Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment is expected to witness the highest growth during the forecast period due to increasing prevalence of asthma across the globe.

Based on the end user, the market is segmented into hospitals & clinics and homecare settings. Homecare settings is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to technological advancements in pulmonary drug delivery devices that enable their use in the home care settings. Digital inhalers allow patients to maintain medical records and dosage of the drug administered; this also enable patients to share this record with physicians.

Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing aging population, increasing adoption of an unhealthy lifestyle, increasing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region. Presently, North America is expected to dominate the market. This is due to increasing technological developments, increasing prevalence of chronic respiratory and supportive reimbursement policies in the form of Medicare and Medicaid.

The key players in the pulmonary drug delivery market focus on various organic and inorganic growth strategies such as agreements, collaborations, expansions, product launches & approvals, and partnerships.

The key players in this market are Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).

Apart from the comprehensive geographical analysis, product analysis, and market sizing the report also provides a competitive landscape that covers the growth strategies adopted by industry players in the last three years. In addition, the company profiles comprise basic views on the key players and their product portfolios, developments, and strategies adopted. The abovementioned market research data, current market sizes, and forecast of future trends will help key players and new entrants make informed decisions regarding product offerings, geographical focus, change in strategic approach, and R&D investments for innovations in products and technologies, and levels of output to remain successful.

Research Coverage:

The report defines, describes, and forecasts the pulmonary drug delivery market on the basis of formulations, canister type, application, end user, and regions. It provides detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges). The study tracks and analyzes competitive developments such as acquisitions, product developments, and expansions in the pulmonary drug delivery market across four main regions, namely, North America, Asia, Europe, and the Rest of the World (RoW).

Reasons to Buy the Report:

The report on "Pulmonary Drug Delivery" provides quantitative information for clients seeking market size information on various segments of the pulmonary drug delivery market.

This report also provides access to the quantitative data on pulmonary drug delivery market. This report covers -

  • Current and forecast assessment of the global pulmonary drug delivery market
  • Country-wise assessment of each of the segments
  • Global market share analysis of major segments of the pulmonary drug delivery market
  • Adoption trends of pulmonary drug delivery in major geographic segments
  • Five-year coverage of strategic developments of top players in the pulmonary drug delivery market
  • Product portfolio mapping of leading players in the pulmonary drug delivery market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. KEY DATA FROM SECONDARY SOURCES
  • 2.4. KEY DATA FROM PRIMARY SOURCES
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. PULMONARY DRUG DELIVERY: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: PULMONARY DRUG DELIVERY MARKET, BY APPLICATION (2016)
  • 4.3. PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE (2016 VS. 2021)
  • 4.4. PULMONARY NEBULIZERS MARKET, BY TYPE (2016-2021)
  • 4.5. GEOGRAPHIC SNAPSHOT: PULMONARY DRUG DELIVERY MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. MARKET DRIVERS
      • 5.2.1.1. Increasing preference for pulmonary drug delivery as an alternate route of drug delivery
      • 5.2.1.2. Increasing focus on the development of smart/digital inhalers
      • 5.2.1.3. Increasing incidence of respiratory diseases
    • 5.2.2. MARKET RESTRAINTS
      • 5.2.2.1. Regulatory issues
      • 5.2.2.2. Pricing pressure 35 
    • 5.2.3. MARKET OPPORTUNITIES
      • 5.2.3.1. Emerging markets
      • 5.2.3.2. Growth in online marketing channels
    • 5.2.4. MARKET CHALLENGES
      • 5.2.4.1. Issues with the stability of drugs
      • 5.2.4.2. Deposition of aerosolized particles

6. PULMONARY DRUG DELIVERY MARKET, BY FORMULATION

  • 6.1. INTRODUCTION
  • 6.2. TYPE
    • 6.2.1. SUSPENSION AEROSOLS
    • 6.2.2. SOLUTION AEROSOLS
    • 6.2.3. DRY POWDER FORMULATIONS
  • 6.3. DEVICE TYPE
    • 6.3.1. METERED DOSE INHALERS (MDIS)
    • 6.3.2. DRY POWDER INHALERS (DPIS)
    • 6.3.3. NEBULIZERS
      • 6.3.3.1. Jet Nebulizers
      • 6.3.3.2. Ultrasonic Nebulizers
      • 6.3.3.3. Soft mist nebulizers

7. PULMONARY DRUG DELIVERY MARKET, BY CANISTER TYPE

  • 7.1. INTRODUCTION
  • 7.2. PLAIN CANISTERS
  • 7.3. COATED CANISTER

8. PULMONARY DRUG DELIVERY MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • 8.3. ASTHMA
  • 8.4. CYSTIC FIBROSIS
  • 8.5. OTHER APPLICATIONS

9. PULMONARY DRUG DELIVERY MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITALS & CLINICS
  • 9.3. HOME CARE SETTINGS 61 

10. PULMONARY DRUG DELIVERY MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. U.K.
    • 10.3.3. FRANCE
    • 10.3.4. REST OF EUROPE
  • 10.4. ASIA
    • 10.4.1. CHINA
    • 10.4.2. INDIA
    • 10.4.3. JAPAN
    • 10.4.4. REST OF ASIA
  • 10.5. REST OF THE WORLD

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET RANK ANALYSIS
  • 11.3. COMPETITIVE SITUATIONS AND TRENDS
    • 11.3.1. COLLABORATIONS
    • 11.3.2. PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • 11.3.3. ACQUISITIONS
    • 11.3.4. EXPANSIONS

12. COMPANY PROFILES (Overview, Products and Services, Financials, Strategy & Development)*

  • 12.1. INTRODUCTION
  • 12.2. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 12.3. 3M
  • 12.4. GLAXOSMITHKLINE PLC
  • 12.5. ASTRAZENECA PLC
  • 12.6. BOEHRINGER INGELHEIM
  • 12.7. MERCK & CO., INC.
  • 12.8. NOVARTIS AG
  • 12.9. OMRON CORPORATION 134 
  • 12.10. SUNOVION PHARMACEUTICALS INC. (A PART OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
  • 12.11. CIPLA INC.

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13. APPENDIX

  • 13.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: COMPANIES DEVELOPING SMART/DIGITAL INHALER TECHNOLOGIES
  • TABLE 2: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 3: SUSPENSION AEROSOLS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: SOLUTION AEROSOLS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 5: DRY POWDER FORMULATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE , 2014-2021 (USD MILLION)
  • TABLE 7: METERED DOSE INHALERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: DRY DOSE INHALERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: NEBULIZERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 10: NEBULIZERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: JET NEBULIZERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: SOFT MIST NEBULIZERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 15: PLAIN CANISTERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: COATED CANISTERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 18: PULMONARY DRUG DELIVERY MARKET SIZE FOR COPD, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: PULMONARY DRUG DELIVERY MARKET SIZE FOR ASTHMA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: PULMONARY DRUG DELIVERY MARKET SIZE FOR CYSTIC FIBROSIS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: PULMONARY DRUG DELIVERY MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 23: PULMONARY DRUG DELIVERY MARKET SIZE FOR HOSPITALS & CLINICS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: PULMONARY DRUG DELIVERY MARKET SIZE FOR HOME CARE SETTINGS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 28: NORTH AMERICA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 30: NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 31: NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 32: U.S.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 33: U.S.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 34: U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 35: U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 36: U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 37: CANADA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 38: CANADA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 39: CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 40: CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 41: CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 42: EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 43: EUROPE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 44: EUROPE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 45: EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 46: EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 47: EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 48: GERMANY: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 49: GERMANY: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 50: GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 51: GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 52: GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 53: U.K.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 54: U.K.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 55: U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 56: U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 57: U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 58: FRANCE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 59: FRANCE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 60: FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 61: FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 62: FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 63: ROE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 64: ROE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 65: ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 66: ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 67: ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 68: ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 69: ASIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 70: ASIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 71: ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 72: ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 73: ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 74: CHINA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 75: CHINA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 76: CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 77: CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 78: CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 79: INDIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 80: INDIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 81: INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 82: INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 83: INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 84: JAPAN: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 85: JAPAN: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 86: JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 87: JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 88: JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 89: ROA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 90: ROA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 91: ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 92: ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 93: ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 94: ROW: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 95: ROW: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014-2021 (USD MILLION)
  • TABLE 96: ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014-2021 (USD MILLION)
  • TABLE 97: ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 98: ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 99: MARKET RANKING OF THE KEY PLAYERS IN THE PULMONARY DRUG DELIVERY MARKET (2015)
  • TABLE 100: COLLABORATIONS, 2014-2016
  • TABLE 101: PRODUCT LAUNCHES AND REGULATORY APPROVALS, 2014-2016
  • TABLE 102: ACQUISITIONS, 2014-2016
  • TABLE 103: EXPANSIONS, 2014-2016
  • TABLE 104: EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2016 VS. 2021
  • FIGURE 7: GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2016 VS. 2021
  • FIGURE 8: GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2016 VS. 2021
  • FIGURE 9: GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2016 VS. 2021
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE PULMONARY DRUG DELIVERY MARKET
  • FIGURE 11: INCREASING INCIDENCE OF RESPIRATORY DISEASES IS A KEY MARKET DRIVER FOR PULMONARY DRUG DELIVERY
  • FIGURE 12: ASTHMA FORMS THE LARGEST APPLICATION SEGMENT IN THE PULMONARY DRUG DELIVERY MARKET
  • FIGURE 13: METERED-DOSE INHALERS TO COMMAND THE LARGEST MARKET SHARE IN 2016
  • FIGURE 14: JET NEBULIZERS TO DOMINATE THE PULMONARY NEBULIZERS MARKET IN 2016
  • FIGURE 15: CHINA TO REGISTER HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 16: PULMONARY DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: U.K.: ESTIMATED NUMBER OF PEOPLE DIAGNOSED WITH ASTHMA (2004-2012)
  • FIGURE 18: NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 19: EUROPE: PULMONARY DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 20: ASIA: PULMONARY DRUG DELIVERY MARKET SNAPSHOT
  • FIGURE 21: KEY DEVELOPMENTS IN THE PULMONARY DRUG DELIVERY MARKET, 2014-2016
  • FIGURE 22: BATTLE FOR MARKET SHARE: COLLABORATIONS ACCOUNTED FOR THE LARGEST SHARE OF THE TOTAL DEVELOPMENTS DURING 2014 TO 2016
  • FIGURE 23: GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS IN THE PULMONARY DRUG DELIVERY MARKET
  • FIGURE 24: TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2015)
  • FIGURE 25: 3M: COMPANY SNAPSHOT (2015)
  • FIGURE 26: GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2015)
  • FIGURE 27: ASTRAZENECA PLC: COMPANY SNAPSHOT (2015)
  • FIGURE 28: BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2015)
  • FIGURE 29: MERCK & CO., INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 30: NOVARTIS AG: COMPANY SNAPSHOT (2015)
  • FIGURE 31: OMRON CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 32: SUMITOMO DAINIPPON PHARMA CO., LTD.: COMPANY SNAPSHOT (2015)
  • FIGURE 33: CIPLA INC.: COMPANY SNAPSHOT (2016)
Back to Top